Loading
Everything OnCo dates to 1997: 76 entries, 25 landmarks, 15 papers, 11 companies founded and 10 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
76 dated entries in OnCo fall in 1997: 25 landmarks, 15 papers, 11 companies founded, 10 approvals, 6 journals founded, 4 trials reported, 2 papers listed on people's pages, 1 law or regulation, 1 technology and 1 regulatory event.
Of those, 1 to the day and 75 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Thrombocythaemia secondary to myeloproliferative neoplasms
Prevention of nausea and vomiting from moderately emetogenic chemotherapy (oral); intravenous chemotherapy indication removed in 2010
External genital and perianal warts
Advanced breast cancer after tamoxifen (letrozole)
Prevention of severe thrombocytopenia and reduction of platelet transfusions after myelosuppressive chemotherapy in non-myeloid malignancies. Withdrawn in 2011
Treatment and prevention of postmenopausal osteoporosis
Relapsed follicular lymphoma; first antibody approved for cancer
Relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan
Prevention of recurrence of malignant pleural effusion after drainage (Sclerosol aerosol; sterile powder 2003)
Metastatic breast cancer in postmenopausal women with ER-positive or unknown tumours
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Letrozole approved for advanced breast cancer
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
United States, guidance.
The year reported on trial records, with the headline result the record gives.
24 percent reduction in the relative risk of death and an absolute two-year survival gain of nine percentage points, from 20 to 29 percent (p = 0.004); in squamous cancers a 34 per...
82b: 10-year locoregional recurrence 9% vs 32%; overall survival 54% vs 45%.
Four-year failure rate 0.7 per cent after surgery against 7.5 per cent after radiotherapy (p=0.003), with a good cosmetic result in 87 against 69 per cent by the patient's judgemen...
Five-year local recurrence 11 against 27 percent, with better overall survival.
The publication year on key paper records.
Burris HA 3rd, Moore MJ, Andersen J, et al. Journal of Clinical Oncology.
Kinzler KW, Vogelstein B. Nature.
Simon MP, Pedeutour F, Sirvent N, et al. Nature Genetics.
Bower M, Newlands ES, Holden L, et al. Journal of Clinical Oncology.
Bolla M, Gonzalez D, Warde P, et al. New England Journal of Medicine.
Lengauer C, Kinzler KW, Vogelstein B. Nature.
Bonnet D, Dick JE. Nature Medicine.
Swedish Rectal Cancer Trial, Cedermark B, Dahlberg M, et al. New England Journal of Medicine.
Unknown. Journal of Clinical Oncology.
Levine AJ. Cell.
Tallman MS, Andersen JW, Schiffer CA, et al. New England Journal of Medicine.
Overgaard M, Hansen PS, Overgaard J, et al. New England Journal of Medicine.
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Clinical Cancer Research.
Weaver VM, Petersen OW, Wang F, et al. The Journal of cell biology.
Struewing JP, Hartge P, Wacholder S, et al. New England Journal of Medicine.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Biochemical recurrence of prostate cancer
Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)
Dermatofibrosarcoma protuberans
Desmoid tumour. Tejpar and colleagues.
Papillary renal cell carcinoma
Localised prostate cancer, high and very high risk
Triple-negative breast cancer (TNBC). Struewing and colleagues, 5,318 volunteers, three founder variants carried by over 2 percent of the population; Górski described the Polish BR...
Pancreatic ductal adenocarcinoma. Clinical benefit response over 5-FU; the standard for 14 years.
Metastatic pancreatic ductal adenocarcinoma
Extragonadal germ cell tumour. The International Germ Cell Cancer Collaborative Group defined good, intermediate and poor risk; a mediastinal non-seminomatous primary alone places...
Testicular germ cell tumours. Updated in 2021 with LDH and age refinements.
Non-seminomatous germ cell tumour
Lower-risk myelodysplastic syndromes
Myelodysplastic syndromes / neoplasms (MDS). Greenberg's International Prognostic Scoring System combines blasts, cytogenetics and cytopenias.
Central nervous system germ cell tumours (germinoma and non-germinomatous). Basis for risk-adapted therapy in Japan and later international trials.
Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4). Chandrasekharappa and colleagues, Science; menin identified.
Kaposi sarcoma
Follicular lymphoma. First monoclonal antibody for cancer, in relapsed indolent lymphoma.
Non-Hodgkin lymphoma (all types). Anti-CD20 rituximab for relapsed follicular lymphoma; added to CHOP it raised cure rates in diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma
Skin cancer (all types). 347 patients randomised at the Institut Gustave Roussy: four-year failure 0.7 against 7.5 per cent and a better cosmetic result after surgery on four of fi...
Colorectal cancer. 1,168 patients; five-year local recurrence 11 versus 27 percent and overall survival 58 versus 48 percent, against surgery that was not standardised.
Prostate cancer. An immunohistochemical survey shows PSMA is detectable in prostatic epithelium, duodenal mucosa and some renal tubules and almost nowhere else, while falling in de...
Colorectal cancer. Microsatellite-stable colorectal cancers gain or lose chromosomes above 10^-2 per chromosome per division, a dominant and continuing defect distinct from mismatc...
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Planegg-Martinsried
Durham, NC
Shijiazhuang
Berkeley Heights, NJ
Ireland
Paris
Neu-Isenburg
Memphis, TN
Bellinzona
Bologna
Oakwood Village, OH
The founded year on journal records.
Springer (Springer-Verlag Tokyo)
Elsevier Masson
Oncology Nursing Society
Lippincott Williams & Wilkins (Wolters Kluwer)
Elsevier
Springer Nature (Nature Portfolio)
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Nature Medicine
Science